Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $22.86, for a total value of $228,600.00. Following the completion of the transaction, the insider now directly owns 1,250,148 shares in the company, valued at $28,578,383.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Day One Biopharmaceuticals Stock Up 0.7 %

Shares of DAWN stock opened at $22.98 on Thursday. The stock's fifty day simple moving average is $20.80 and its 200 day simple moving average is $20.83. Day One Biopharmaceuticals, Inc. has a one year low of $5.44 and a one year high of $28.35.

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last posted its quarterly earnings data on Monday, November 7th. The company reported ($0.53) EPS for the quarter, hitting analysts' consensus estimates of ($0.53). Equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -2.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Wall Street Analyst Weigh In

DAWN has been the topic of a number of research reports. Piper Sandler boosted their price objective on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Sunday. Bank of America initiated coverage on Day One Biopharmaceuticals in a research report on Thursday, December 1st. They set a "buy" rating and a $34.00 price objective on the stock. Needham & Company LLC initiated coverage on Day One Biopharmaceuticals in a research report on Wednesday, December 14th. They set a "buy" rating and a $40.00 price objective on the stock. HC Wainwright boosted their price objective on Day One Biopharmaceuticals from $35.00 to $45.00 and gave the company a "buy" rating in a research report on Monday. Finally, The Goldman Sachs Group boosted their price objective on Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a "buy" rating in a research report on Monday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of "Buy" and an average target price of $43.50.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Featured Articles

• Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
• Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
• Why Hershey Is a Sweet Recession Stock
• Will Amazon Stock Be Delivering for Investors in 2023?
• The Analysts Shift Trucking Sentiment Back into Forward
• The Institutions Book A Flight With Boeing

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.